CASTLE BIOSCIENCES, INC. Net Income (Loss) Available to Common Stockholders, Diluted
CASTLE BIOSCIENCES, INC. (CSTL) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$4.28 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2021-05-10
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-03-31 was -$4.28M, a 850.88% decline year-over-year.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2020-12-31 was -$4.89M, a 337.91% decline year-over-year.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2020-09-30 was -$4.59M, a 711.87% decline year-over-year.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2020-03-31 was $570.00K.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$10.28M.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for fiscal 2019 was -$1.80M.
- CASTLE BIOSCIENCES, INC. net income (loss) available to common stockholders, diluted for fiscal 2018 was -$10.16M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2021-03-31 | -$4.28M 10-Q · filed 2021-05-10 | -$9.17M derived: sum of 2 quarters · filed 2021-05-10 | -$13.76M derived: sum of 3 quarters · filed 2021-05-10 | |||
| 2020-12-31 | -$4.89M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$9.48M derived: sum of 2 quarters · filed 2021-03-11 | -$10.28M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | -$4.59M 10-Q · filed 2020-11-09 | -$5.39M 10-Q · filed 2020-11-09 | ||||
| 2020-03-31 | $570.00K 10-Q · filed 2021-05-10 | $2.63M derived: sum of 2 quarters · filed 2021-05-10 | $3.38M derived: sum of 3 quarters · filed 2021-05-10 | |||
| 2019-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $2.81M derived: sum of 2 quarters · filed 2021-03-11 | -$1.80M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $750.00K 10-Q · filed 2020-11-09 | $749.64K 10-Q · filed 2019-11-12 | -$3.86M 10-Q · filed 2020-11-09 | -$3.86M 10-Q · filed 2019-11-12 | ||
| 2018-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | -$1.59M derived: sum of 2 quarters · filed 2020-03-10 | -$10.16M 10-K · filed 2020-03-10 | |||
| 2018-09-30 | -$4.46M 10-Q · filed 2019-11-12 | -$13.02M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |